Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir and Ulonivirine vs BIC/FTC/TAF in Treatment-Naïve HIV-1
NCT07266831Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of islatravir, ulonivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Dec 2025; status: recruiting.
02
Drugs
islatravirulonivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07266831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266831.